Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Database
Language
Document Type
Year range
1.
Journal of Investigative Medicine ; 71(1):510, 2023.
Article in English | EMBASE | ID: covidwho-2319804

ABSTRACT

Case Report: Since the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic, there has been much work to understand the negative effects of SARS-CoV-2 on tissues expressing the Angiotensin Converting Enzyme-2 (ACE2) receptor, including the placenta. However, there is limited information regarding placental pathology findings in mothers with COVID-19 and the effects of SARS-CoV-2 on the placenta. The available research reports effects on the fetus ranging from minimal to intrauterine fetal demise. Case Description: A 4680g baby boy was born at 38+1 weeks of gestation to 36y old G4P1021 female via repeat cesarian section. The pregnancy was complicated by advanced maternal age, chronic hypertension with superimposed pre-eclampsia with severe features, BMI of 80, and SARS-CoV-2 infection. The mother had mild COVID-19 symptoms and did not require hospitalization or oxygen support. Prenatal ultrasounds were limited due to body habitus. At the time of delivery, there was clear amniotic fluid. Upon delivery the infant was cyanotic and limp and was brought to the warmer immediately. Non-invasive positive pressure ventilation was initiated at 5 minutes of life with improvement in infant color and oxygen saturation. He was then admitted to the Neonatal Intensive Care Unit (NICU). APGARs were 2, 3, 5, and 7 at 1, 5, 10, and 15 minutes respectively. Cord gases showed severe metabolic acidosis. The patient was diagnosed with hypoxic-ischemic encephalopathy (HIE) and therapeutic hypothermia was initiated. Both the NICU and obstetric teams were unable to identify a clear perinatal cause of HIE in this patient. Later, the placenta pathology report revealed a large placenta for estimated gestational age corresponding to the 75th percentile, villous parenchyma with focal chorangiosis and thrombi, with unremarkable fetal membrane and three vessel umbilical cord. The cause of HIE was then thought to be due to the placental thrombi likely caused by SARS-CoV-2 infection. Discussion(s): Fetal vascular malperfusion and fetal vascular thrombus have been noted as a common finding in the placentas of pregnant women who test positive for SARS-CoV-2. There are various causes of HIE, from maternal, placental and fetal factors. This patient had no clinically evident hypoxic event, but information was limited due to the lack of monitoring of the fetus in utero. Given the mother's SARS-CoV-2 infection and the placental pathology findings, it is likely that the cause of this patient's HIE was related to the effects on the placenta from SARS-CoV-2. Conclusion(s): As more information comes to light about the effects of SARS-CoV-2 on the placenta, it is important to consider a maternal SARS-CoV-2 infection during pregnancy as a cause of HIE in a newborn.

2.
Italian Journal of Gynaecology and Obstetrics ; 35(Supplement 1):64, 2023.
Article in English | EMBASE | ID: covidwho-2281510

ABSTRACT

Objective. As the SARS-CoV-2 Pandemic has widely changed pregnancy experience and assessment, the inpatient and outpatient services have had to be re-organized. Since March 2020, Careggi University Hospital (CUH) has provided a dedicated COVID-pathway: spaces for women with unknown swab status and a COVID-19 ward delivery room. The aim of this study is to analyze the inpatient and outpatient COVID-19 related activities in CUH. Materials and Methods. We prospectively collected data from consecutive COVID-19 pregnancies referred from 2020 to 2022, included in the local branch of the ItOSS surveillance. All patients experienced COVID-19 in pregnancy at various stages of severity and gestational ages. Results. From March 2020 to June 2022, 165 COVID-19 deliveries occurred (169 newborns), while 16 pregnant positive women were admitted without delivering. A single emergency C-section (CS) was performed because of Sars-CoV-2 related ARDS, 15 women experienced serious maternal morbidity and 5 needed ECMO. A single maternal death occurred four months after delivery (C-section). Considering ECMO supported cases during pregnancy or postpartum, the first one tested positive for COVID-19 during the second trimester. She developed ARDS and required ECMO for 38 days. She was discharged in good general conditions and a CS at term was performed following obstetric indication. The second patient developed COVID-19-related ARDS at 28 weeks of gestation and experienced a precipitous vaginal delivery at 31 weeks+6 days of gestation while on ECMO. She was discharged 1 month later in good general conditions. The third patient was an obese (BMI 38) 43-year-old woman who had performed an IVF with embryo donation;she tested positive at 38 weeks+2 days of gestation. A CS was performed because of the worsening of her condition. After the delivery she was admitted in ICU and she underwent ECMO. She died 143 days after the CS by sepsis and multiple organ failure (MOF). For all these pregnancies neonatal outcomes were positive. No perinatal death occurred and only one baby tested positive for SARS-CoV-2 infection at nasal swab sampling (case 3). The anesthesiology team performed neuroassial analgesia intrapartum in all the positive women who needed/requested it. Monoclonal Antibodies (mAbs) have been widely used to treat mild to moderate COVID-19 outpatients (NIH and RCOG recommendations) at risk for developing severe disease. Regarding this specifical therapy, an essential role in the management of the pregnant outpatient was played by the Infectious Disease Department. All patients above 28 weeks requiring hospitalization received LMWH prophylaxis, which was administrated under 28 weeks only in presence of additional risk factors (obesity, IVF, etc.). All new mothers received a ten days LMWH prophylaxis. On the outpatient side, we performed 22 teleconsultations, 43 obstetric ultrasounds (including I trimester screening), 90 obstetric checks with clinical evaluation and home therapy management, 32 fetal monitoring and 47 naso-pharingeal swabs. Conclusions. At Careggi Hospital Maternal Department an extensive re-organization of inpatient and outpatient services has been performed in order to guarantee good practice and management of all pregnant women during the SARS-CoV-2 pandemic. This was only possible thanks to a wide multidisciplinary group which enhanced every professional.

3.
Donald School Journal of Ultrasound in Obstetrics and Gynecology ; 15(4):377-379, 2021.
Article in English | EMBASE | ID: covidwho-1614153

ABSTRACT

Aim and objective: In this article, we explore the current practices, challenges, and opportunities to the integration of telehealth in the field of ultrasonography for the education of the physician in the care of obstetrics and gynecology patients. Telemedicine and telehealth (TM/TH) have been used in obstetrics and gynecology primarily as an adjunct service to the usual care for encounters that require a minimal physical examination. Background: Telemedicine and telehealth are commonly interchangeable terms referring to the provision of clinical services at a distance. Before the coronavirus disease-2019 (COVID-19) pandemic, the United States (US) was seeing modest but significant growth in the use of TM/TH. The COVID-19 pandemic appears to have accelerated the implementation of TM/TH. Review results: Teleradiology, in particular, the use of asynchronous (i.e., store-and-forward) technology, is also used for maternal–fetal medicine consultations. Other TM/TH modalities such as fetal echocardiography, remote fetal monitoring, and remote patient monitoring (RPM) are slowly becoming more popular. Despite the ample benefits of TM/TH, undergraduate and graduate medical training on TM/TH and point-of-care ultrasound (POCUS) skills have been historically deficient. Multiple challenges remain for the expansion of TM/TH services including regulatory, reimbursement, and licensing policy. For the incorporation of ultrasound in TM/TH visits, a greater infrastructure is needed. Considerations for this infrastructure include rural broadband internet access and modernization of the information technology infrastructure capable of exchanging ultrasound images electronically in a secure and HIPPA-compliant interface. Conclusion: There is ample reason to remain optimistic about the future of TM/TH in the field of ultrasonography and clinical care for obstetrics and gynecology patients. To take advantage of these opportunities, it is imperative that the current challenges to the expansion of TM/TH, including the gaps in the medical education system, be addressed systematically. Clinical and Educational significance: Advances in POCUS, intelligent navigation, and teleoperated ultrasound technology provide a prospect of opportunities to advance TM/TH care while expanding educational opportunities. The most recent expansion of TM/TH after the COVID-19 pandemic is likely to launch TM/TH into a new level of market penetration, making the need for undergraduate and graduate medical education on TM/TH skills ever more relevant.

SELECTION OF CITATIONS
SEARCH DETAIL